RxDoctor Payments DataLook up a doctor →

Cedric Franklin Rutland, MD

Critical Care Medicine · Riverside, CANPI 1811122799

Payments from drug & device makers

$3,249,104in general payments, 2019–2025

Across 2,638 payments — averaging $1231.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1M
  • Sanofi$794K
  • AstraZeneca$515K
  • Regeneron Healthcare Solutions, Inc.$480K
  • Boehringer Ingelheim$177K
  • Pfizer$66K
  • plus $207K from 54 others
$3,680in research payments, 2019–2025

Across 1 payment — averaging $3679.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$4K

What the payments were for

  • Consulting fees$902,77228%
  • Speaking & faculty fees$1,922,76159%
  • Grants$70,0002%
  • Travel & lodging$290,0419%
  • Food & beverage$62,7942%
  • Education$7180%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK504$1,010,592
Sanofi497$793,996
AstraZeneca475$514,993
Regeneron Healthcare Solutions, Inc.463$479,781
Boehringer Ingelheim196$176,935
Pfizer33$65,577
Modernatx, Inc.11$54,245
Genentech USA, Inc.48$36,994
Sanofi-aventis U.S. LLC13$27,585
Medtronic29$26,613
Olympus America Inc.19$11,292
United Therapeutics Corporation21$8,136
Amgen30$7,676
Regeneron14$6,654
Takeda Pharmaceuticals U.S.A., Inc.30$6,355
Verona Pharma, Inc.4$6,344
Veran Medical Technologies, Inc.15$4,780
Chiesi USA, Inc.1$2,200
Sanofi Pasteur Inc.1$1,233
AbbVie(2 entities)40$883
Genentech, Inc.12$848
Octapharma USA, Inc.12$560
Novartis18$462
Grifols USA, LLC31$462
Noah Medical Corporation2$434
Johnson & Johnson(2 entities)11$308
Shionogi Inc11$265
Baxter Healthcare7$230
Lilly USA, LLC10$199
Teva Pharmaceuticals USA, Inc.2$175
Aero US Inc1$167
Mylan Specialty L.p.5$160
Abiomed1$150
Inari Medical, Inc.6$149
La Jolla Pharmaceutical Company2$144
Advanced Respiratory, Inc7$135
Philips North America LLC8$130
Intuitive Surgical1$123
Pulmonx Corporation1$122
Harmony Biosciences LLC2$116
Merck7$106
Biohaven Pharmaceutical Holding Company Ltd.4$102
Insmed, Inc.4$71
ANI Pharmaceuticals, Inc.2$67
Circassia Inc.2$56
Nabriva Therapeutics, PLC3$52
Cook Medical LLC1$51
Exact Sciences2$42
Radius Health, Inc.2$41
Novo Nordisk2$38
Liquidia Technologies, Inc.1$33
Melinta Therapeutics, LLC2$29
Pinnacle Biologics, Inc1$25
Elucent Medical1$22
Invivyd Inc1$22
Vifor Pharma, Inc.1$21
Xeris Pharmaceuticals, Inc.1$20
Esperion Therapeutics, Inc.1$19
Tactile Systems Technology Inc1$17
Tolmar, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,249,104 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$80,889
Medicare patients
127
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$330,516
Dupixent SyringeDupilumab34$124,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$78,094
Dupixent PenDupilumab16$73,512
GammakedImmune Globul G/Gly/Iga Avg 4624$69,572
Pirfenidone16$60,044
NucalaMepolizumab13$48,940
Breztri AerosphereBudesonide/Glycopyr/Formoterol72$47,757
Ambrisentan13$15,493
AirsupraAlbuterol Sulfate/Budesonide17$7,783
Spiriva RespimatTiotropium Bromide11$5,488
SymbicortBudesonide/Formoterol Fumarate15$3,540
Mycophenolate Mofetil29$2,316
Wixela InhubFluticasone Propion/Salmeterol27$2,265
Albuterol Sulfate HfaAlbuterol Sulfate60$1,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$176,935$336,00438 claims
GSKTrelegy Ellipta, Nucala$1,010,592$127,034111 claims
AstraZenecaBreztri Aerosphere, Airsupra, Symbicort$514,993$59,080104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →